Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 13.00
-1.15 (-8.13%)
Nov 2, 2026, 5:29 PM CET
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 127.95 | 152.35 | 148.1 | 238.73 | 57.62 | 10.71 |
| 127.95 | 152.35 | 148.1 | 238.73 | 57.62 | 10.71 | |
Revenue Growth | -38.80% | 2.87% | -37.96% | 314.33% | 438.03% | - |
Cost of Revenue | 108.13 | 62.81 | 18.23 | 203.34 | - | - |
Gross Profit | 19.82 | 89.55 | 129.87 | 35.39 | 57.62 | 10.71 |
Selling, General & Admin | 26.49 | 43.82 | 40.81 | 40.03 | 31.54 | 31.4 |
Research & Development | 92.3 | 117.87 | 162.01 | 305.78 | 199.65 | 160.62 |
Other Operating Expenses | -53.84 | -52.21 | 9.4 | -13.71 | -20.91 | -4.85 |
Operating Expenses | 64.96 | 109.48 | 212.21 | 332.11 | 210.27 | 187.17 |
Operating Income | -45.14 | -19.93 | -82.34 | -296.72 | -152.65 | -176.46 |
Interest Expense | -4.66 | -12.04 | -30.62 | -18.5 | -2.58 | -2.64 |
Interest & Investment Income | 0.71 | 0.71 | 0.5 | 2.41 | 0.3 | - |
Currency Exchange Gain (Loss) | -8.32 | -8.32 | -14.87 | -9.15 | -13.56 | -4.13 |
Other Non Operating Income (Expenses) | -4.36 | -4.36 | -2.39 | -0.06 | -0.01 | -0.01 |
Pretax Income | -61.76 | -43.93 | -129.72 | -322.03 | -168.51 | -183.23 |
Income Tax Expense | 0.09 | 2.23 | 11.59 | - | - | - |
Earnings From Continuing Operations | -61.85 | -46.17 | -141.31 | -322.03 | -168.51 | -183.23 |
Earnings From Discontinued Operations | -0.83 | 173.41 | -124.91 | -66.14 | -4 | -5.15 |
Net Income | -62.68 | 127.24 | -266.22 | -388.17 | -172.51 | -188.38 |
Net Income to Common | -62.68 | 127.24 | -266.22 | -388.17 | -172.51 | -188.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 21 | 16 | 10 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 21 | 16 | 10 | 0 | 0 | 0 |
Shares Change | -98.94% | 67.03% | 4184.59% | 12.26% | 8.38% | 30.25% |
EPS (Basic) | -3.04 | 7.74 | -27.06 | -1690.32 | -843.34 | -998.04 |
EPS (Diluted) | -3.04 | 7.74 | -27.06 | -1690.32 | -843.34 | -998.54 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 67.5 | -250.69 | -134.23 | -413.47 | -205.53 | -247.29 |
Free Cash Flow Per Share | 3.28 | -15.25 | -13.64 | -1800.48 | -1004.76 | -1310.16 |
Gross Margin | 15.49% | 58.77% | 87.69% | 14.82% | 100.00% | 100.00% |
Operating Margin | -35.28% | -13.08% | -55.60% | -124.29% | -264.94% | -1647.75% |
Profit Margin | -48.99% | 83.52% | -179.76% | -162.60% | -299.41% | -1759.04% |
Free Cash Flow Margin | 52.76% | -164.55% | -90.64% | -173.20% | -356.72% | -2309.16% |
EBITDA | -48.48 | -19.64 | -73.16 | -287.62 | -145.21 | -171.93 |
EBITDA Margin | -37.89% | -12.89% | -49.40% | -120.48% | -252.03% | - |
D&A For EBITDA | -3.35 | 0.29 | 9.18 | 9.1 | 7.44 | 4.53 |
EBIT | -45.14 | -19.93 | -82.34 | -296.72 | -152.65 | -176.46 |
EBIT Margin | -35.28% | -13.08% | -55.60% | -124.29% | -264.94% | - |